about
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsRegulation of mammary epithelial cell homeostasis by lncRNAsPy2T murine breast cancer cells, a versatile model of TGFβ-induced EMT in vitro and in vivoThe tumor microenvironment in esophageal cancerChanging genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationshipsSystems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"Tumor microenvironment complexity: emerging roles in cancer therapy.Wnt signaling in triple negative breast cancer is associated with metastasisStromal PDGFR-α Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth.Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancersIdentification of novel dysregulated key genes in Breast cancer through high throughput ChIP-Seq data analysis.Distinct breast cancer subtypes in women with early-onset disease across racesPeroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues.Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancerRepression of Zeb1 and hypoxia cause sequential mesenchymal-to-epithelial transition and induction of aid, Oct4, and Dnmt1, leading to immortalization and multipotential reprogramming of fibroblasts in spheresInvasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progressionIntratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expressionChromosome-breakage genomic instability and chromothripsis in breast cancerPrognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.MiR-34b is associated with clinical outcome in triple-negative breast cancer patientsInhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.Proteogenomics connects somatic mutations to signalling in breast cancer.Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia.Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies.The Changing World of Breast Cancer: A Radiologist's Perspective.Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases.PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools.Characterising the tumour morphological response to therapeutic intervention: an ex vivo model.Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified.Mass spectrometry imaging for in situ kinetic histochemistry.Cell Fate Decisions During Breast Cancer Development.Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsSTAT signaling in different breast cancer sub-types.
P2860
Q26738643-FEA18F72-E5EF-449A-9086-467E493C6513Q27011533-538354B9-7EBA-4310-85F9-6BCCBCF2DEF6Q27340972-2F0B7C59-32D5-4F92-8BCF-94572F4C5D08Q28077074-50B30029-F662-4512-A867-B1D5E27F89F3Q28387022-6CCE772C-A499-48F8-A9F2-2980F0099529Q28391909-6DAD87D3-BEF6-4EE5-9D34-4D6C7ED24207Q30419311-8EA3FB77-FE08-4E7D-9C40-895D911FF9BFQ30597238-4185014E-F881-4D49-8D93-2851EF02A691Q33714718-703D6412-C7EC-4AAC-A208-7F752BF184B1Q33779282-0913DAFC-46E1-47AE-AEC5-5AAF57ECC2C1Q33789460-B1AD82CF-8432-404D-BACC-DB4806B2F2BEQ33932660-9F4E9DAA-8622-487A-9084-00E5A6E079C6Q34571496-B60E850E-F5B6-48FB-8A52-0AB35C6C0ABDQ34573232-F0523CE4-E860-48C2-BD64-6E3BC52D2F85Q34663710-19406E58-FFA8-4501-8D2B-6BC42E67A6CAQ34698985-AA40627A-A5EB-4DA3-ADCD-F74CE412CD87Q34706851-2D841B66-6F15-4663-9880-45DF6A220B06Q34994693-BE3CAAEF-17EE-4346-AE60-2B7F4ED7F08DQ34999819-80DCA75B-8379-44FE-B9E9-F026CA9A1DE2Q35149179-872CE783-E2D0-414E-824C-F256DEB40913Q35204806-C0A2EEA2-F066-4803-98D6-F7FF2B13BC23Q35832173-EDD1919C-71B6-4E06-8B03-5F1FA71ACDDCQ35832458-A6FB6D2C-2A23-44CE-8A98-71FE55D656EDQ35950656-D310512D-4E8E-4991-A3BD-917821599A89Q35952745-9E4696BB-9CE6-44A9-BA60-5073C2BFDDBEQ36037203-C1F88586-B1F5-403C-B3B3-462364B4DAD1Q36171326-06E04F70-C8D2-45C0-9588-75F90D035E77Q36191982-B393FCD9-E69E-41DC-BEAD-0F85A4842E78Q36217490-AECE44D1-85E0-4724-B482-F7764CD4B17BQ36378535-13D8350A-42B7-4CE1-8D2D-147C2F0321E0Q36389184-4F6338CA-CA53-48A4-AFEF-BB2A1D681A38Q36480693-91286A8E-FB52-44DF-9E52-F2961FD3CF27Q36486054-657DABD5-B1C1-4AB1-9846-AC3AA977152EQ36750271-2B0029A9-9EF6-40F6-9CAD-08F59564653BQ36764431-42EFBDFE-0E3E-41B8-BEB9-61EB4081EE87Q36823886-9247B32E-E251-49ED-9B19-90303D021848Q36843205-149617F8-4449-4B90-9819-D8BF46E33B30Q36924396-8BF133E1-1B6F-4F0D-B1F9-E01FC64657FFQ37075632-EF3E1E8C-C5B5-413D-9D6E-3E8019F36F89Q37086768-E0AC23FD-AC27-4FEB-A55E-5D254570E95F
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Breast cancer - one term, many entities?
@ast
Breast cancer - one term, many entities?
@en
type
label
Breast cancer - one term, many entities?
@ast
Breast cancer - one term, many entities?
@en
prefLabel
Breast cancer - one term, many entities?
@ast
Breast cancer - one term, many entities?
@en
P2860
P356
P1476
Breast cancer - one term, many entities?
@en
P2093
Morag Park
Nicholas R Bertos
P2860
P304
P356
10.1172/JCI57100
P407
P577
2011-10-03T00:00:00Z